Bentracimab

Bentracimab
Monoclonal antibody
Type	Fab fragment
Source	Human
Target	Ticagrelor, AR-C124910XX (the active metabolite)
Clinical data
Other names	PB2452, MEDI2452
Routes of; administration	Intravenous infusion
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2260568-31-6;
PubChem SID	405226665;
DrugBank	DB16659;
UNII	1TBM83QR9S;
KEGG	D11799;
Chemical and physical data
Formula	C2095H3240N560O674S12
Molar mass	47440.93 g·mol−1

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y₁₂ inhibitor and is sold under the brand name Brilinta among others).^[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.^[3]^[4] It is not commercially available.

References

^ "Specialist Pharmacy Service: Bentracimab". National Health Service. 10 January 2021.
^ "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". Cardiovascular News. 2021-01-29.
^ Clinical trial number NCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" at ClinicalTrials.gov
^ Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, et al. (August 2021). "Ticagrelor use and practice patterns among Canadian cardiac surgeons". Journal of Cardiac Surgery. 36 (8): 2793–2801. doi:10.1111/jocs.15636. PMID 34028081.